The Role of GLP-1 in Satiety Perception in Humans
Lead sponsor
Asset
Avexitide
Listed sites
1
Recruiting sites
-
Actual enrollment
-
Study population
Obesity / overweight
Eligibility highlights
•BMI 18.5-24.9
Primary endpoint
-
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Inclusion criteria
1. Male or female between 18-29 years of age
2. BMI between 18.5-24.9 kg/m2
3. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion criteria
1. Chronic health conditions, including diabetes and kidney disease.
2. Current dieting for weight loss or restrained eating
3. History of obesity, eating disorders, or weight loss surgery
4. Random blood glucose >140
5. Pregnancy or use of oral contraceptives
6. Current smoker
7. Recreational drug use or alcohol use of > 1 drink per day for females, > 2 per day for males
8. Food allergy or intolerance to study foods.
9. Medications known to alter appetite (e.g., amphetamines, atypical antipsychotics) or gastric emptying (e.g., metoclopromide)
10. Contraindications to MRI, such as implanted metal or claustrophobia.
11. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Endpoints (0)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
No endpoints recorded for this trial.
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.